Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:11 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 1,385 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Granulocyte-colony stimulating factor Clear all

Conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Diffuse
Interventions: GM-CSF, CHOP, Rituximab; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Diarrhea, Gastrointestinal Complications, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: filgrastim, cyclophosphamide; Biological · Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 1 Year to 21 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Fanconi Anemia
Interventions: anti-thymocyte globulin, filgrastim, busulfan, cyclophosphamide, fludarabine phosphate, methylprednisolone, Hematopoietic stem cell transplantation; Biological · Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 44 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lymphoma
Interventions: carmustine, cytarabine, etoposide, thiotepa, stem cell transplant, G-CSF; Drug · Procedure
Lead sponsor: Alliance for Clinical Trials in Oncology; Other
Eligibility: 18 Years to 75 Years
Enrollment: 113 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 126
States / cities: Anchorage, Alaska • Burbank, California • La Jolla, California + 81 more

Conditions: Breast Cancer
Interventions: filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 59 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Leukemia
Interventions: filgrastim, oblimersen sodium, cytarabine, fludarabine phosphate; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 16 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 1999
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Breast Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: allogeneic GM-CSF-secreting breast cancer vaccine, recombinant interferon alfa, cyclophosphamide; Biological · Drug
Lead sponsor: Wiseman Research Initiatives LLC; Industry
Eligibility: 18 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 3
States / cities: Glendale, California • Los Angeles, California

Conditions: Esophageal Cancer, Gastric Cancer
Interventions: filgrastim, cisplatin, fluorouracil, paclitaxel, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Radiation Therapy Oncology Group; Network
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 66
States / cities: Mobile, Alabama • Phoenix, Arizona • Duarte, California + 54 more

Conditions: Prostate Cancer
Interventions: pTVG-AR, gm-csf; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 3
States / cities: New Brunswick, New Jersey • Seattle, Washington • Madison, Wisconsin

Conditions: Platinum Sensitive Ovarian Cancer, Ovarian Cancer
Interventions: FRα peptide plus Adjuvant (GM-CSF), Adjuvant (GM-CSF) Alone; Biological · Drug
Lead sponsor: Marker Therapeutics, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 18
States / cities: Birmingham, Alabama • Phoenix, Arizona • Newport Beach, California + 14 more

Conditions: Systemic Scleroderma
Interventions: Anti-Thymocyte Globulin, Autologous Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Filgrastim, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Plerixafor, Quality-of-Life Assessment, Questionnaire Administration; Biological · Procedure · Drug + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 70 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 12
States / cities: Duarte, California • Los Angeles, California • Denver, Colorado + 5 more

Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: aldesleukin, filgrastim, sargramostim, busulfan, cyclophosphamide, melphalan, paclitaxel, thiotepa, bone marrow ablation with stem cell support, in vitro-treated peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: Up to 56 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: hTERT vaccine, GM-CSF, PCV, T cell infusion, GM-CSF, PCV, T cell infusion; Biological
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 2
States / cities: Baltimore, Maryland • Philadelphia, Pennsylvania

Conditions: Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2002
U.S. locations: 3
States / cities: Boston, Massachusetts

Conditions: Myeloma
Interventions: Palifermin, Dexamethasone, Gemcitabine, Busulfan, Melphalan, Stem Cell Transplant, G-CSF; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
Interventions: Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection; Drug · Biological · Procedure + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Severe Combined Immunodeficiency
Interventions: Transplant Conditioning with Mobilization Only, Transplant Conditioning with Mobilization and Alemtuzumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: Up to 3 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-Hodgkin's Lymphoma
Interventions: Filgrastim SD/01, Paclitaxel, Topotecan; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Breast Cancer
Interventions: GP2 peptide + GM-CSF vaccine, GM-CSF (sargramostim), AE37 + GM-CSF vaccine; Biological
Lead sponsor: San Antonio Military Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 456 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 11
States / cities: Washington D.C., District of Columbia • Honolulu, Hawaii • Baltimore, Maryland + 7 more

Conditions: Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions: L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim; Drug · Biological
Lead sponsor: Children's Oncology Group; Network
Eligibility: 2 Years to 31 Years
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 42
States / cities: Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more

Conditions: Multiple Myeloma
Interventions: GPC-100, Propranolol, G-CSF; Drug
Lead sponsor: GPCR Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 10
States / cities: La Jolla, California • Gainesville, Florida • Indianapolis, Indiana + 7 more

Conditions: Leukemia, Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, dexamethasone, doxorubicin hydrochloride, methotrexate, vincristine sulfate; Biological · Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2006
U.S. locations: 12
States / cities: Little Rock, Arkansas • Palo Alto, California • Chicago, Illinois + 9 more

Conditions: Lymphoma
Interventions: filgrastim, cyclophosphamide, cytarabine, daunorubicin hydrochloride, doxorubicin hydrochloride, etoposide, leucovorin calcium, methotrexate, pegaspargase, prednisone, thioguanine, vincristine sulfate, radiation therapy; Biological · Drug · Radiation
Lead sponsor: Children's Oncology Group; Network
Eligibility: Up to 20 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1994 – 2007
U.S. locations: 30
States / cities: Long Beach, California • Los Angeles, California • Orange, California + 24 more

Conditions: Infertility, Female
Interventions: G-CSF, Saline; Drug
Lead sponsor: Center for Human Reproduction; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma

Cyclophosphamide in Treating Young Patients With Severe Autoimmune Enteropathy

Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

Combination Chemotherapy With or Without Autologous Stem Cell Transplant in Treating Patients With Central Nervous System B-Cell Lymphoma

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Vaccine Therapy in Treating Patients With HER2/Neu Positive or Negative Stage IV Breast Cancer or Other HER2/Neu Positive Cancers

Combination Chemotherapy Plus Radiation Therapy With or Without Fluorouracil in Treating Patients With Cancer of the Esophagus or Stomach

A Phase I Study of a DNA Vaccine Encoding Androgen Receptor Ligand-Binding Domain (AR LBD) +/-GMCSF

Folate Receptor Alpha Peptide Vaccine With GM-CSF Versus GM-CSF Alone in Patients With Platinum Sensitive Ovarian Cancer

Scleroderma Treatment With Autologous Transplant (STAT) Study

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma

High-dose ICE With Amifostine

High-Dose Gemcitabine, Busulfan and Melphalan With Hematopoietic-Cell Support for Patients With Poor-Risk Myeloma

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

Hematopoietic Stem Cell Transplantation (HSCT) for Children With SCID Utilizing Alemtuzumab, Plerixafor & Filgrastim

A Phase II Study of Paclitaxel and Topotecan With Filgrastim-SD/01 Support For Relapsed and Refractory Aggressive Non-Hodgkin's Lymphoma

Vaccine Therapy in Treating Patients With Breast Cancer

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

Ph2, Study to Assess the Safety and Efficacy of GPC 100 and Propranolol With and Without G-CSF for the Mobilization of Stem Cells in Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

Combination Chemotherapy in Treating Children With Stage III or Stage IV Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia

Combination Chemotherapy in Treating Children With Lymphoma

Effect of Colony Stimulating Factor on Poor Endometrial Development During IVF